DeepBio has obtained approval from the ethics committee of the University of Utah to conduct a real-world study to validate the performance of its AI-based prostate cancer diagnosis software with ARUP Laboratories.

DeepBio has won approval from the University of Utah’s review board to conduct a prospective study to assess the performance of its AI-based prostate cancer diagnosis software, DeepDx-Prostate, with ARUP Laboratories.
DeepBio has won approval from the University of Utah’s review board to conduct a prospective study to assess the performance of its AI-based prostate cancer diagnosis software, DeepDx-Prostate, with ARUP Laboratories.

At the University of Utah ARUP Laboratories, the company intends to assess the impact of DeepDx-Prostate in a real-world setting with three pathologists who will give an initial diagnosis of the slides of core needle biopsy samples of the prostate using a microscope.

Pathologists will then review the same slides again with the existing diagnostic method plus DeepDx-Prostate and evaluate whether DeepDx-Prostate could increase pathologists' diagnostic accuracy and efficiency in detecting cancer. 

"Most of the studies that evaluate the performance of AI-based medical solutions are retrospectively done based on the existing diagnosis data," DeepBio CEO Kim Sun-woo said. "This prospective study is valuable as it can validate the overall performance of DeepDx-Prostate in a real-world setting, and we expect our solution to provide pathologists with faster and more consistent diagnostic aid when applied in the field."

Beatrice Knudsen, Medical Director of Digital and Computational Pathology at ARUP Laboratories and the principal investigator of the study, said, "We have high expectations for the impact of DeepDx-Prostate in the clinical practice environment and anticipate the study to draw data on how pathologists can use AI-based solutions to enhance efficiency and accuracy of diagnosis."

DeepBio plans for further collaborations in various cancer diagnosis, prognosis, and prediction studies with ARUP Laboratories since the university accepted the joint research deal in May.

The company is conducting joint studies with several leading universities at home and abroad, including Stanford University, and is preparing to provide services to more pathologists by working with companies developing pathology image management systems.

Copyright © KBR Unauthorized reproduction, redistribution prohibited